These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 25532942)

  • 1. Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum.
    Shen AS; Peterhof E; Kind P; Rütten A; Zelger B; Landthaler M; Berneburg M; Hafner C; Groesser L
    Hum Pathol; 2015 Feb; 46(2):272-6. PubMed ID: 25532942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
    Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
    Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
    Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
    Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syringocystadenoma Papilliferum of the Anogenital Area and Buttocks: A Report of 16 Cases, Including Human Papillomavirus Analysis and HRAS and BRAF V600 Mutation Studies.
    Konstantinova AM; Kyrpychova L; Nemcova J; Sedivcova M; Bisceglia M; Kutzner H; Zamecnik M; Sehnalkova E; Pavlovsky M; Zateckova K; Shvernik S; Spurkova Z; Michal M; Kerl K; Kazakov DV
    Am J Dermatopathol; 2019 Apr; 41(4):281-285. PubMed ID: 30398985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
    Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
    Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
    Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
    J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
    Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
    Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
    Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
    Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.
    Knobbe CB; Reifenberger J; Reifenberger G
    Acta Neuropathol; 2004 Dec; 108(6):467-70. PubMed ID: 15517309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell.
    Groesser L; Herschberger E; Sagrera A; Shwayder T; Flux K; Ehmann L; Wollenberg A; Torrelo A; Bagazgoitia L; Diaz-Ley B; Tinschert S; Oschlies I; Singer S; Mickler M; Toll A; Landthaler M; Real FX; Hafner C
    J Invest Dermatol; 2013 Aug; 133(8):1998-2003. PubMed ID: 23337891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naevus sebaceus: a mosaic RASopathy.
    Aslam A; Salam A; Griffiths CE; McGrath JA
    Clin Exp Dermatol; 2014 Jan; 39(1):1-6. PubMed ID: 24341474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Profiling of Syringocystadenocarcinoma Papilliferum Reveals RAS-Activating Mutations.
    Cornejo KM; Hutchinson L; O'Donnell P; Meng X; Tomaszewicz K; Shalin SC; Cassarino DS; Chan MP; Quinn TR; Googe PB; Nazarian RM
    Arch Pathol Lab Med; 2024 Feb; 148(2):215-222. PubMed ID: 37074845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of B-RAF and N-RAS mutations in human melanoma.
    Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
    J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nevus sebaceous and syringocystadenoma papilliferum.
    Greer KE; Bishop GF; Ober WC
    Arch Dermatol; 1976 Feb; 112(2):206-8. PubMed ID: 183608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mutations are common somatic events in melanocytic nevi.
    Kumar R; Angelini S; Snellman E; Hemminki K
    J Invest Dermatol; 2004 Feb; 122(2):342-8. PubMed ID: 15009715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas.
    Bläker H; Helmchen B; Bönisch A; Aulmann S; Penzel R; Otto HF; Rieker RJ
    Scand J Gastroenterol; 2004 Aug; 39(8):748-53. PubMed ID: 15513360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients.
    Mochel MC; Hammond MR; Frederick DT; Alora-Palli MB; Piris A; Flaherty KT; Hoang MP
    J Am Acad Dermatol; 2015 Sep; 73(3):491-9.e2. PubMed ID: 26190239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
    Arnault JP; Mateus C; Escudier B; Tomasic G; Wechsler J; Hollville E; Soria JC; Malka D; Sarasin A; Larcher M; André J; Kamsu-Kom N; Boussemart L; Lacroix L; Spatz A; Eggermont AM; Druillennec S; Vagner S; Eychène A; Dumaz N; Robert C
    Clin Cancer Res; 2012 Jan; 18(1):263-72. PubMed ID: 22096025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.